Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

Inactivation of the p53 tumor suppressor is a frequent event in tumorigenesis. In most cases, the p53 gene is mutated, giving rise to a stable mutant protein whose accumulation is regarded as a hallmark of cancer cells. Mutant p53 proteins not only lose their tumor suppressive activities but often gain additional oncogenic functions that endow cells with growth and survival advantages. Interestingly, mutations in the p53 gene were shown to occur at different phases of the multistep process of malignant transformation, thus contributing differentially to tumor initiation, promotion, aggressiveness, and metastasis. Here, the authors review the different studies on the involvement of p53 inactivation at various stages of tumorigenesis and highlight the specific contribution of p53 mutations at each phase of cancer progression.

[1]  R. Ralhan,et al.  Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous‐cell carcinoma in India , 2000, International journal of cancer.

[2]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Oren,et al.  New plays in the p53 theater. , 2011, Current opinion in genetics & development.

[4]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[5]  G. Giglia-Mari,et al.  TP53 mutations in human skin cancers , 2003, Human mutation.

[6]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[7]  K. Danenberg,et al.  Tumor suppressor gene P53 mutations in human prostate cancer , 1995, The Prostate.

[8]  Manuel Serrano,et al.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.

[9]  P. Hainaut,et al.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.

[10]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[11]  P. Hainaut,et al.  Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.

[12]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[13]  J. Fraumeni,et al.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.

[14]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[15]  T. Jacks,et al.  The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.

[16]  H. Ananthaswamy,et al.  p53 and the pathogenesis of skin cancer. , 2007, Toxicology and applied pharmacology.

[17]  G. Wahl,et al.  Linking the p53 tumor suppressor pathway to somatic cell reprogramming , 2009, Nature.

[18]  Carl W. Miller,et al.  Human p53 gene localized to short arm of chromosome 17 , 1986, Nature.

[19]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[20]  S. Hirohashi,et al.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.

[21]  D. Sidransky,et al.  Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.

[22]  V. Rotter,et al.  Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.

[23]  W. Deppert,et al.  Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis , 2007, International journal of cancer.

[24]  V. Rotter,et al.  Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells , 2011, Cell Death and Differentiation.

[25]  J. Milner,et al.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.

[26]  C. Harris,et al.  Geographic variation of p53 mutational profile in nonmalignant human liver. , 1994, Science.

[27]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[28]  B. Wasylyk,et al.  Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. Hamelin,et al.  Correlations between p53‐protein accumulation, serum antibodies and gene mutation in colorectal cancer , 1999, International journal of cancer.

[30]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[31]  T. Soussi,et al.  p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity , 1998, International journal of cancer.

[32]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[33]  Lubin,et al.  p53 antibodies in patients with various types of cancer: assay, identification, and characterization. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. Soussi Analysis of p53 Gene Alterations in Cancer: A Critical View , 2007 .

[35]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[36]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[37]  T. Hieken,et al.  Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. , 2001, Surgery.

[38]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[39]  R H Hruban,et al.  Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[41]  S. Hirohashi,et al.  p53 gene mutation spectrum in hepatocellular carcinoma. , 1992, Cancer research.

[42]  V. Rotter,et al.  Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.

[43]  H. Yamazaki,et al.  Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. , 1996, Environmental health perspectives.

[44]  C. Cohen,et al.  Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[45]  V. Rotter,et al.  Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy , 2008, Cell cycle.

[46]  T. Uchida,et al.  p53 mutations and prognosis in bladder tumors. , 1995, The Journal of urology.

[47]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[48]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[49]  Shalom Madar,et al.  p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation , 2008, Molecular systems biology.

[50]  H. Höfler,et al.  Genetic Alterations in Presumptive Precursor Lesions of Breast Carcinomas , 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[51]  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[52]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[53]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[54]  Y Sawamura,et al.  Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. , 1999, Neuro-oncology.

[55]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[56]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Rotter,et al.  Review P53 Is Balancing Development, Differentiation and De-differentiation to Assure Cancer Prevention , 2022 .

[58]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[59]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[60]  M. Olivier,et al.  TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.

[61]  V. Rotter,et al.  TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.

[62]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[63]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[64]  D. Evans,et al.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.

[65]  E. Appella,et al.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[66]  V. Rotter,et al.  p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.

[67]  P. Hainaut,et al.  25 years of p53 research , 2005 .

[68]  N. Nishishita,et al.  Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. , 2010, Experimental hematology.

[69]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[70]  Y. Wang,et al.  Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. , 2009, Cancer cell.

[71]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[72]  P. Laurent-Puig,et al.  Circulating free tumor DNA and colorectal cancer. , 2010, Gastroenterologie clinique et biologique.

[73]  V. Rotter,et al.  Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50 , 1980, Journal of virology.

[74]  C. Wild,et al.  Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. , 1993, Environmental health perspectives.

[75]  M. Blasco,et al.  The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.

[76]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[77]  V. Rotter,et al.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.

[78]  P. Knoepfler Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine , 2009, Stem cells.

[79]  H. Shimada,et al.  Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. , 2001, The European journal of surgery = Acta chirurgica.

[80]  B. Milleron,et al.  Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[82]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[83]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[84]  Xiaolei Yin,et al.  Two supporting factors greatly improve the efficiency of human iPSC generation. , 2008, Cell stem cell.

[85]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[86]  D. Evans,et al.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. , 1999, American journal of human genetics.

[87]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[88]  M. Ozturk,et al.  p53 mutation as a source of aberrant β-catenin accumulation in cancer cells , 2002, Oncogene.

[89]  H. Ananthaswamy,et al.  P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. , 2008, Advances in experimental medicine and biology.

[90]  R. Carroll,et al.  Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. , 1979, Virology.

[91]  D. Louis The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[92]  P. Cerutti,et al.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[93]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[94]  T. Soussi,et al.  Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.

[95]  Eytan Domany,et al.  The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation , 2005, Molecular systems biology.

[96]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[97]  P. May,et al.  Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.

[98]  Ker-Chau Li,et al.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.

[99]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[100]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[101]  H. Bismuth,et al.  Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma , 1999, British Journal of Cancer.

[102]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[103]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[104]  W Atkin,et al.  Stool DNA-based colorectal cancer detection: finding the needle in the haystack. , 2001, Journal of the National Cancer Institute.

[105]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[106]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[107]  L. Timchenko,et al.  Intracellular signaling and hepatocellular carcinoma. , 2011, Seminars in cancer biology.

[108]  W. Lutz,et al.  Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. , 1990, Carcinogenesis.

[109]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[110]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[111]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[112]  P. Shubik,et al.  A New, Quantitative, Approach to the Study of the Stages of Chemical Carcinogenesis in the Mouse's Skin , 1947, British Journal of Cancer.

[113]  Li-juan Zhang,et al.  Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. , 2008, World journal of gastroenterology.

[114]  Varda Rotter,et al.  Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. , 2010, Discovery medicine.

[115]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[116]  V. Rotter,et al.  Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. , 1993, Oncogene.

[117]  H. Brenner,et al.  Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.

[118]  J. Goedert,et al.  249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma , 2005, Oncogene.

[119]  V. Rotter,et al.  p53 is a regulator of macrophage differentiation , 2004, Cell Death and Differentiation.

[120]  V. Rotter,et al.  p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner , 2008, PloS one.

[121]  L. Mao Genetic alterations as clonal markers for bladder cancer detection in urine , 1996, Journal of cellular biochemistry. Supplement.

[122]  M. Hollstein,et al.  Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. , 1996, Cancer research.